早期非小细胞肺癌立体定向放疗中PERCIST/RECIST反应标准与SUVmax的预后价值
该回顾性研究纳入95例接受SBRT的早期NSCLC患者,评估PERCIST/RECIST反应及治疗前后SUVmax对生存和肿瘤控制的影响。结果显示PERCIST/RECIST反应与PFS、LC、LRC相关,而SUVmax(无论治疗前、后或变化值)均不能预测任一终点;多因素分析中治疗前GTV≥30 cm³与更差生存相关。
要点
- PERCIST/RECIST反应与PFS、LC、LRC显著相关,但与OS、DC无关。
- 治疗前、后SUVmax及ΔSUVmax均不能预测OS、PFS、LC、LRC或DC。
- 多因素分析中治疗前GTV≥30 cm³与更差生存结局显著相关。
核心结论
- PERCIST/RECIST反应与接受SBRT的早期NSCLC患者更好的LC和PFS相关;治疗前后SUVmax不能预测疾病控制或生存。
研究设计与样本
- 回顾性研究纳入95例(53例女性,42例男性)在本机构接受SBRT的早期NSCLC患者,中位年龄75岁。
- 肺部SBRT采用3-5次分割,总剂量48-60 Gy,BEDα/β=10Gy至少100 Gy。
- 采用Kaplan-Meier曲线和log-rank检验进行单变量分析,Cox回归分析评估年龄、性别、治疗前GTV、影像最长肿瘤径和CCI对生存的影响。
主要发现
- 自SBRT结束起中位OS和PFS分别为15.4个月和11.9个月。
- 单变量分析中PERCIST/RECIST反应与PFS(p=0.039)、LC(p=0.007)、LRC(p=0.015)相关,但与OS(p=0.21)和DC(p=0.94)无关。
- 治疗前SUVmax、治疗后SUVmax(截断值<5 vs ≥5、<4 vs ≥4、<3 vs ≥3)及ΔSUVmax(多种截断值)均不能预测OS、PFS、LC、LRC或DC。
- 多因素分析中,校正其他混杂变量后,治疗前GTV≥30 cm³与更差生存结局显著相关。
关键数值与推荐
- PERCIST/RECIST反应评估与PFS、LC、LRC的统计学关联(p值分别为0.039、0.007、0.015)。
- SUVmax截断值<5 vs ≥5、<4 vs ≥4、<3 vs ≥3及ΔSUVmax多种截断值均未显示预测价值。
- 治疗前GTV≥30 cm³在多因素分析中与更差生存显著相关。
临床怎么用
- 对于接受SBRT的早期NSCLC患者,可依据PERCIST/RECIST反应评估预后,反应良好者LC和PFS更优。
- 不宜单独依据治疗前、后SUVmax或ΔSUVmax预测疾病控制或生存。
- 治疗前GTV≥30 cm³提示生存结局较差,可考虑更密切随访或强化治疗策略。
局限性
- 本研究为单中心回顾性研究,样本量95例,可能存在选择偏倚。
- SUVmax分析采用多种截断值,但均为探索性,未进行多重比较校正。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to evaluate the prognostic impact of Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) and Response Evaluation Criteria in Solid Tumors (RECIST) and of pre- and post-treatment maximum Standard Uptake Value (SUVmax) in regards to survival and tumor control for patients treated for early-stage non-small cell lung cancer (ES-NSCLC) with stereotactic body radiotherapy (SBRT). METHODS: This is a retrospective review of patients with ES-NSCLC treated at our institution using SBRT. Lobar, locoregional, and distant failures were evaluated based on PERCIST/RECIST and clinical course. Univariate analysis of the Kaplan-Meier curves for overall survival (OS), progression free survival (PFS), lobar control (LC), locoregional control (LRC), and distant control (DC) was conducted using the log-rank test. Pre- and post-treatment SUVmax were evaluated using cutoffs of < 5 and ≥ 5, < 4 and ≥ 4, and < 3 and ≥ 3. ∆SUVmax was also evaluated at various cutoffs. Cox regression analysis was conducted to evaluate survival outcomes based on age, gender, pre-treatment gross tumor volume (GTV), longest tumor dimension on imaging, and Charlson Comorbidity Index (CCI). RESULTS: This study included 95 patients (53 female, 42 male), median age 75. Lung SBRT was delivered in 3-5 fractions to a total of 48-60 Gy, with a BEDα/β = 10Gy of at least 100 Gy. Median OS and PFS from the end of SBRT was 15.4 and 11.9 months, respectively. On univariate analysis, PERCIST/RECIST response correlated with PFS (p = 0.039), LC (p = 0.007), and LRC (p = 0.015) but not OS (p = 0.21) or DC (p = 0.94). Pre-treatment SUVmax and post-treatment SUVmax with cutoff values of < 5 and ≥ 5, < 4 and ≥ 4, and < 3 and ≥ 3 did not predict for OS, PFS, LC, LRC, or DC. ∆SUVmax did not predict for OS, PFS, LC, LRC, or DC. On multivariate analysis, pre-treatment GTV ≥ 30 cm3 was significantly associated with worse survival outcomes when accounting for other confounding variables. CONCLUSIONS: PERCIST/RECIST response is associated with improved LC and PFS in patients treated for ES-NSCLC with SBRT. In contrast, pre- and post-treatment SUVmax is not predictive of disease control or survival.
引用
- Pierson C, Grinchak T, Sokolovic C, et al. Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy. Radiat Oncol. 2018. PMID: 29486779. doi:10.1186/s13014-018-0980-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。